Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on developing treatments for chronic hepatitis B (cHBV) infection. Its core pipeline includes imdusiran, an RNAi therapeutic targeting HBV antigens, and AB-101, an oral PD-L1 inhibitor aimed at reactivating immune response. Arbutus also develops proprietary lipid nanoparticle (LNP) delivery technology, licensed to third parties, and generates revenue through royalties and licensing agreements. The company serves global markets with a focus on innovative antiviral therapies.
This description was generated via AI from an annual report. Updated about 1 year ago.